Overview

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

Status:
Not yet recruiting

Trial end date:
2026-10-01

Target enrollment:

Participant gender:

Summary

This is the first-in-human, multicenter, open-label Phase I/II study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of FB849 alone and in combination with pembrolizumab in subjects with advanced solid tumors for whom no standard therapy is available.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

1ST Biotherapeutics, Inc.

Treatments:

Pembrolizumab